ATE336250T1 - Methoden zur regulierung der serin/threonin protein kinase funktion mit 5- azaquinoxalinderivaten - Google Patents

Methoden zur regulierung der serin/threonin protein kinase funktion mit 5- azaquinoxalinderivaten

Info

Publication number
ATE336250T1
ATE336250T1 AT98948606T AT98948606T ATE336250T1 AT E336250 T1 ATE336250 T1 AT E336250T1 AT 98948606 T AT98948606 T AT 98948606T AT 98948606 T AT98948606 T AT 98948606T AT E336250 T1 ATE336250 T1 AT E336250T1
Authority
AT
Austria
Prior art keywords
azaquinoxaline
derivatives
methods
protein kinase
threonine protein
Prior art date
Application number
AT98948606T
Other languages
German (de)
English (en)
Inventor
Gerald Mcmahon
Bernhard Kutscher
Eckhard Gunther
Harald App
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Application granted granted Critical
Publication of ATE336250T1 publication Critical patent/ATE336250T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT98948606T 1997-10-06 1998-10-05 Methoden zur regulierung der serin/threonin protein kinase funktion mit 5- azaquinoxalinderivaten ATE336250T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6112397P 1997-10-06 1997-10-06

Publications (1)

Publication Number Publication Date
ATE336250T1 true ATE336250T1 (de) 2006-09-15

Family

ID=22033733

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98948606T ATE336250T1 (de) 1997-10-06 1998-10-05 Methoden zur regulierung der serin/threonin protein kinase funktion mit 5- azaquinoxalinderivaten

Country Status (30)

Country Link
US (2) US6180631B1 (https=)
EP (1) EP1028729B1 (https=)
JP (1) JP2001518496A (https=)
KR (1) KR100633270B1 (https=)
CN (1) CN1169527C (https=)
AR (1) AR013542A1 (https=)
AT (1) ATE336250T1 (https=)
AU (1) AU757585B2 (https=)
BG (1) BG64969B1 (https=)
BR (1) BR9814814A (https=)
CA (1) CA2306257C (https=)
CY (1) CY1106223T1 (https=)
CZ (1) CZ298775B6 (https=)
DE (1) DE69835612T2 (https=)
DK (1) DK1028729T3 (https=)
ES (1) ES2268791T3 (https=)
HU (1) HUP0100302A3 (https=)
IL (2) IL135103A0 (https=)
MX (1) MXPA03011007A (https=)
NO (1) NO316598B1 (https=)
NZ (1) NZ503431A (https=)
PL (1) PL192039B1 (https=)
PT (1) PT1028729E (https=)
RU (1) RU2223753C2 (https=)
SK (1) SK4722000A3 (https=)
TR (2) TR200000906T2 (https=)
TW (1) TWI245765B (https=)
UA (1) UA71555C2 (https=)
WO (1) WO1999017759A2 (https=)
ZA (1) ZA988961B (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) * 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
WO2001032658A1 (en) * 1999-11-02 2001-05-10 Ajinomoto Co., Inc. Polyazanaphthalene compound and medicinal use thereof
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
AU2003270727A1 (en) * 2002-09-17 2004-04-08 Luna Innovations, Inc. Remote temperature sensing of small volume and related apparatus thereof
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
WO2004113274A2 (en) * 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
DE102004022383A1 (de) * 2004-05-06 2005-12-01 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen
AU2004240747B2 (en) 2003-05-23 2008-01-03 Zentaris Gmbh Novel pyridopyrazines and use thereof as kinase modulators
AU2004246800B2 (en) * 2003-06-13 2008-12-04 Novartis Ag 2-aminopyrimidine derivatives as Raf kinase inhibitors
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
AU2006313701B2 (en) 2005-11-11 2012-05-31 Aeterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
WO2010003308A1 (zh) * 2008-07-10 2010-01-14 卞化石 一氧化氮及其信息传递系统在制备恶性肿瘤靶向治疗药物中的应用
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2508184A1 (en) 2011-04-06 2012-10-10 Æterna Zentaris GmbH Pyridopyrazine derivatives and their use
GB201118656D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
RU2655604C2 (ru) 2013-01-11 2018-05-29 Фуджифилм Корпорэйшн Азотсодержащее гетероциклическое соединение или его соль
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
MX373150B (es) 2014-03-26 2020-04-21 Astex Therapeutics Ltd Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r).
JP6752715B2 (ja) 2014-03-26 2020-09-09 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 組合せ
RU2743074C2 (ru) 2014-08-01 2021-02-15 Нуэволюшон А/С Соединения, активные по отношению к бромодоменам
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
DK3353177T3 (da) 2015-09-23 2020-08-24 Janssen Pharmaceutica Nv Tricykliske heterocykler til behandling af cancer
AU2016328693B2 (en) 2015-09-23 2021-03-11 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
US12012394B2 (en) * 2018-02-19 2024-06-18 Washington University Alpha-synuclein ligands

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001017A (en) * 1972-12-05 1977-01-04 Ciba-Geigy Ag Process for the photopolymerization of ethylenically unsaturated compounds
US4043819A (en) * 1974-06-11 1977-08-23 Ciba-Geigy Ag Photo-polymerizable material for the preparation of stable polymeric images and process for making them by photopolymerization in a matrix
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3804990A1 (de) * 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
FR2656606B1 (fr) * 1989-12-28 1993-06-25 Roussel Uclaf Utilisation de derives du 9,10-dihydrophenanthrene pour la preparation d'un medicament anti-tumoral, application a titre de medicaments de derives du 9,10-dihydrophenanthrene et produits derives de cette structure.
DE69105495T2 (de) 1990-04-02 1995-04-06 Pfizer Benzylphosphonsäure-tyrosinkinaseinhibitoren.
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0586608A1 (en) 1991-05-29 1994-03-16 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1994003427A1 (en) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5723462A (en) * 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
GB9726851D0 (en) * 1997-12-19 1998-02-18 Zeneca Ltd Human signal transduction serine/threonine kinase

Also Published As

Publication number Publication date
BR9814814A (pt) 2000-10-03
ZA988961B (en) 1999-10-04
MXPA03011007A (es) 2004-02-27
TR200100385T2 (tr) 2002-06-21
CA2306257A1 (en) 1999-04-15
JP2001518496A (ja) 2001-10-16
PT1028729E (pt) 2006-12-29
TR200000906T2 (tr) 2000-11-21
CY1106223T1 (el) 2011-06-08
BG104392A (en) 2000-12-29
EP1028729B1 (en) 2006-08-16
CA2306257C (en) 2007-09-25
SK4722000A3 (en) 2002-06-04
DE69835612D1 (de) 2006-09-28
NO316598B1 (no) 2004-03-01
KR100633270B1 (ko) 2006-10-16
IL135103A0 (en) 2001-05-20
US6727252B1 (en) 2004-04-27
AR013542A1 (es) 2000-12-27
CN1274284A (zh) 2000-11-22
DE69835612T2 (de) 2007-08-16
NO20001748L (no) 2000-04-05
HUP0100302A3 (en) 2006-03-28
BG64969B1 (bg) 2006-11-30
WO1999017759A3 (en) 2000-01-06
NZ503431A (en) 2002-07-26
PL192039B1 (pl) 2006-08-31
US6180631B1 (en) 2001-01-30
ES2268791T3 (es) 2007-03-16
AU9514198A (en) 1999-04-27
CZ298775B6 (cs) 2008-01-23
UA71555C2 (en) 2004-12-15
WO1999017759A2 (en) 1999-04-15
NO20001748D0 (no) 2000-04-05
PL339860A1 (en) 2001-01-15
KR20010030934A (ko) 2001-04-16
HUP0100302A2 (hu) 2001-06-28
RU2223753C2 (ru) 2004-02-20
IL135103A (en) 2007-06-17
TWI245765B (en) 2005-12-21
CZ20001129A3 (cs) 2000-10-11
HK1031836A1 (en) 2001-06-29
DK1028729T3 (da) 2006-12-11
EP1028729A2 (en) 2000-08-23
AU757585B2 (en) 2003-02-27
CN1169527C (zh) 2004-10-06

Similar Documents

Publication Publication Date Title
ATE336250T1 (de) Methoden zur regulierung der serin/threonin protein kinase funktion mit 5- azaquinoxalinderivaten
NO20001555L (no) Azabenzimidazolbaserte forbindelser for modulering av serin/treonin proteinkinasefunksjon
AU7282998A (en) Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds
LTPA2014028I1 (lt) Pakeistieji 3-cianochinolinai kaip proteintirozinkinazės inhibitoriai
DE69838515D1 (de) Aminothiazole zur hemmung cyclinabhängiger kinasen
DE69700302D1 (de) Obturator zum kalibrieren von künstlichen aortenklappen
NO974798D0 (no) Pilotventil med forbedret holdering
DE69800625D1 (de) Anordnung zur Egalisierung von Diensteniveaus zwischen Fähigkeiten
DE69735860D1 (de) Vorrichtung zur Lichtregelung
DE69713295D1 (de) Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung
ID29028A (id) Pirolopirimidina sebagai penghambat protein kinase
DE69711537D1 (de) Zementierstopfen für Bohrloch
NO330986B1 (no) Fremgangsmate for bestemmelse av seismisk polaranisotropi
DE69938163D1 (de) Programmiertes Funkgerät zur automatischen Erfassung von Verzeichnisdaten
DE69720853D1 (de) Verfahren zur Ermittlung von vorzeitigen Zündungen
DE69612888D1 (de) Techniken zur Regelung von entfernten Lampenlasten
DE68909579D1 (de) Methode zur steuerung des luft-kraftstoff-verhaeltnisses.
DE69612006D1 (de) Methode zur gefässerweiterung mit (1,5-inter)arylprostaglandinderivaten
DE69822711D1 (de) Verfarhen zur Herstellung von Dialkylnaphthalinen
DE69727674D1 (de) Zur herstellung von gebrannten mustern
DE69700968D1 (de) Drucker mit Verfahren zur Steuerung derselben
DE3878375D1 (de) Proportionalventil zur verwendung bei blockierverhinderern.
DE69917574D1 (de) Methode zur Immobilisierung von Verbindungen
ATE243857T1 (de) System zur zufuhr von toner
DE69804770D1 (de) Verfahren zur herstellung von halogenkohlenwasserstoffen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1028729

Country of ref document: EP

REN Ceased due to non-payment of the annual fee